Budget FY24: Pharma, healthcare industry seek simplified regulations, research-based incentives

-

New Delhi: Pharmaceutical industry bodies has demanded the government take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget.

Outlining the wishlist for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain said the domestic pharma industry is currently around USD 50 billion in size and aspires to grow to around USD 130 billion by 2030 and USD 450 billion by 2047.

“To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward,” he told PTI.

The budget should outline supportive policies, simplified regulations, and simple GST norms to aid in the development of the pharmaceutical industry, he added. IPA is an alliance of 24 leading domestic pharma companies, including Sun Pharma, Dr Reddy’s Laboratories, Aurobindo Pharma, Cipla, Lupin and Glenmark.

Organisation of Pharmaceutical Producers of India (OPPI) Director General Vivek Sehgal stated that in order to enable the life sciences sector to truly contribute to the ‘Atmanirbhar Bharat’ vision for India, the government needs to incentivise the shift to a discovery-oriented and science-driven approach by providing fiscal incentives and enabling policies.

“The government needs to set in place R&D-focused incentives for the promotion of investment, which remains a constant and necessary ask of the sector,” he said.

Besides, the government can consider providing research-linked incentive schemes for companies making investments to undertake research for new drugs, new chemical entities, and/or new biological entities (NBEs) to combat outbreaks and also explore providing a 200 per cent weighted deduction for companies undertaking such R&D (Research & Development), Sehgal said.

Other considerations such as providing long-pending clarification on the patent box regime to encourage Indian innovators, who developed patents in India and derive benefits worldwide, would also be good initiatives, he added.

OPPI represents research-based pharmaceutical companies in India like AstraZeneca, Johnson & Johnson and Merck, among others.Novartis India Country President Amitabh Dube said that similar to the production linked incentive (PLI) scheme, the government needs to put an impetus on the research-linked incentive scheme as that will improve the accessibility of novel drugs.

As for the healthcare sector, industry body Nathealth President Shravan Subramanyam said that it is imperative to build infrastructural capabilities so that people have greater access to quality and critical healthcare services. Viability gap funding by the government is essential to set up hospitals in tier-1 and tier-2 cities, encouraging increased investment in the healthcare infrastructure, he added.

“We are also witnessing a significant impact on the cost of running business which will affect the sustainability of med-tech organisations. If all payment backlogs both for providers and suppliers under insurance and public procurement are cleared, it would significantly improve the availability of healthcare infrastructure,” he added.

Fortis Healthcare MD & CEO Ashutosh Raghuvanshi said increased policy support is required to encourage, facilitate medical value travel to India. “Another critical area is addressing the shortage of healthcare professionals by identifying doctors, nurses and technical staff willing to work in Tier 2/3 cities and looking at non-traditional ways to double the number of doctors,” he added.

Metropolis Healthcare Promoter and Managing Director Ameera Shah said the Union Budget 2023-2024 should help fuel innovation, R&D, and healthcare expenditure as an investment into future human capital, which will set the pace for propelling the industry forward.

“The government should consider zero-rating GST on healthcare services. It will ensure eligibility for input tax credits, which may help to reduce the cost of said services, and a refund of unutilised input tax credits should also be allowed to provide additional working capital to industry players,” she added.

Roche Diagnostics India MD Narendra Varde said India critically needs to introduce population screening programmes under the Ayushman Bharat scheme for infectious diseases management of HIV, Hepatitis and HPV. Redcliffe Labs Founder & MD Dheeraj Jain said the GST for the healthcare industry needs to be rationalised so that the businesses in the sector may attract more investment and provide services to customers at affordable rates.

Read all the Latest News, Trending News, Cricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.



from Firstpost India Latest News https://ift.tt/Q2sCSDq
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

120 flights delayed, 30 trains running late; Delhi fog & cold wave continue to give shiver to travellers

-
Arrival and departure of 120 flights, both domestic and international, to Delhi airport were affected due to dense fog and cold wave conditions on Wednesday, according to Delhi Airport FIDS (Flight Information Display System). As per the Delhi Airport FIDS, a total of 53 flights, including 21 domestic arrivals, 16 domestic departures, 13 international departures and three international arrivals scheduled are cancelled and not operating due to fog and other operational reasons from and to Indira Gandhi International (IGI) Airport in the national capital on 17 January. #WATCH | Delhi: Several flight operations delayed at IGI airport due to low visibility amid fog. pic.twitter.com/hG1DUKllEt — ANI (@ANI) January 17, 2024 Visuals from the Delhi airport showed passengers waiting outside, checking update of their scheduled flights. There were also some people waiting for flight of their families, friends and loved ones to arrive, which got delayed due to fog. #WATCH | Delhi | Pas
Read more